



## BioAegis Therapeutics Awarded European Patent Protection for the Uses of Plasma Gelsolin to Treat Infections

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) March 13, 2019 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), an endogenous human protein that harnesses the innate immune system to modulate the inflammatory response as well as boost the capacity of immune cells to fight infection announced today that the European Patent Office has issued a patent for the Use of Plasma Gelsolin to Treat Infections. This grant adds to BioAegis’ infection portfolio already covered by patents in the US, China and other territories.

### **About Plasma Gelsolin**

Plasma gelsolin is an abundant circulating protein that enhances macrophage antimicrobial activity, limits the excessive spread of inflammation, and dissolves biofilm that accumulates around damaged cells. Decreased plasma gelsolin levels at presentation are found in patients with diverse infectious and non-infectious inflammatory diseases, who are at high risk for developing serious complications.

### **Plasma Gelsolin and Antimicrobial Resistance**

Because plasma gelsolin therapy is a host-based response that harnesses the body’s immune system representing the body’s first line of defense, antimicrobial resistance is not a factor. Furthermore, several animal studies have shown that the combination of plasma gelsolin and previously ineffective antibiotics has a multiplier effect.

### **About BioAegis Therapeutics**

BioAegis Therapeutics Inc. is a clinical stage, private company whose mission is to exploit a key component of the body’s innate immune system to prevent adverse outcomes in diseases driven by inflammation and infection. BioAegis’ platform of opportunities exploits the multifunctional role of plasma gelsolin, a highly conserved, endogenous human protein.

*This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management’s plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward- looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.*

### **For further information:**

Steven Cordovano, 203-952-6373

Email: [scordovano@bioaegistx.com](mailto:scordovano@bioaegistx.com)

[www.bioaegistx.com](http://www.bioaegistx.com)